Wrong expiry on tropicamide eye drops: what the MHRA Class 3 recall means for QA

What happened

The MHRA has ordered a Class 3 recall of Aspire Pharma's Tropicamide 1% single-dose eye drops (20 x 0.5 ml). Three batches carry an expiry date of April 2027, but the MHRA says the correct date is 31 October 2026.

The record is dated 5 November 2026, after the stated correct expiry. On those dates, the affected stock had already passed its true expiry when the alert appeared. The records do not say when the error was found, how it arose, or how many units were supplied. They give no information on adverse events, and they do not say whether any product was used after 31 October.

Why a Class 3 recall still matters

A Class 3 recall is the lower-urgency tier in the MHRA system, reserved for defects unlikely to cause harm to patients. That classification reflects the MHRA's view of risk. It does not make the defect trivial for quality teams.

An expiry date is the label's main assurance of shelf life. A printed date about six months later than the validated one means every downstream check that relies on the label is working from wrong data. Pharmacy stock rotation, wholesaler quarantine rules and clinic stock checks all read the printed date. Nobody downstream can detect the error without the alert.

Single-dose eye drops are also a product where users and dispensers have little reason to doubt the pack. The point for QA is that the control failed silently. Only the manufacturer's data could show the date was wrong.

The control points to review

The records do not identify the root cause, so any explanation would be speculation. The failure sits in a well-known part of GMP, though: the link between the approved shelf life, the batch record and what gets printed on the pack. Teams can test their own systems at several points.

First, how is the expiry date calculated and who verifies it? Second, is the printed value checked against the batch record by someone independent, and is that check repeated after any line changeover or reprint? Third, does the artwork or coding system allow manual entry of dates? Fourth, is there a documented comparison between the date on the finished pack and the approved shelf life before QP certification?

For marketing authorisation holders using contract packers, the same questions apply across the contract. Quality agreements should say who owns the date verification step and how a discrepancy is escalated.

Context: a day of varied quality and supply notices

Other records from the same day show how many forms a quality or supply problem can take. They are separate cases, and nothing in the records links them to the tropicamide recall.

Health Canada posted a recall of Nova Biomedical StatStrip ketone test strips after affected lots showed more quality control failures in use. It states patient blood results are unaffected. Health Canada also published Type II recalls for a Siemens MAGNETOM Flow.Ace software issue and for further Olympus reusable HF-cable models, the latter with a reminder on service-life instructions. In the Czech Republic, SÚKL circulated a marketing authorisation holder's letter on a vial closure defect affecting CSL Behring's Respreeza 1000 mg. Germany's BfArM listed a Funke Medical field safety notice on a mattress extension, though the public entry gives no detail on the problem or the corrective action.

The ANSM case is closest to a compliance lesson. Its 23 October 2026 decision fined Biocon Biologics France over shortage-notification rules for medicines of major therapeutic interest, following a risk declaration and a 2025 inspection. The records do not give the fine amount. The case is a reminder that regulators check how companies report and communicate problems as well as the problems themselves. Separately, Denmark reports CAPVAXIVE pre-filled syringe supply problems in November 2026, attributed to higher demand.

What to watch

Several points are not yet known. The MHRA entry as summarised in the records does not say how the error occurred, whether other products or batches are affected, or what Aspire Pharma will change. Watch for any follow-up notice or update to the alert.

Teams should also watch how recall instructions reach the point of use. Where a recall concerns a date, the practical risk is stock that stays on shelves because the pack looks in date. Recall readiness therefore depends on fast, batch-level traceability.